Sotera Health Co (SHC) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Sotera Health Co stock $5.20, price $16.01, that is 67.5% below the price, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range $5.95 – $27.28 · fair‑value band $2.17 – $8.18 · the $16.01 price screens above the $5.20 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Sotera Health Co in your weekly email
Every Wednesday you see whether Sotera Health Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs.
Show moreShow less
The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets.
The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems.
The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020.
Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
Stock analysis
Sotera Health Co (SHC) currently trades at $16.01, while our model-based Fair Value estimate is $5.20, 68% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $6.01 per share, and 2 of the 22 models we run sit above the $16.01 price.
Bear case: the Earnings-Based group reads lowest at $2.42, and 20 of the 22 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $2.17 (bear) to $8.18 (bull), the price of $16.01 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Sotera Health Co reported revenue of $1.2B in FY2025 versus $931M in FY2021, a compound +5.7%/yr. Reported net income was $77.9M in FY2025, compounding −9.6%/yr from FY2021.
Key figures
Market cap $4.6B Mid · P/E ratio 26.7 · P/S ratio 3.75 · EPS (TTM) $0.6000 · Net margin 14.1% · Return on equity 27.0% · Return on assets (EBIT) 9.5% (5-year average) · Operating margin 35.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 73 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 18% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −68%, SHC screens richer than that median.
Fair Value models
Bear$2.17Fair Value $5.20Bull$8.18
Price $16.01 · Downside -67.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.5145 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
SaleGTCR CO-INVEST XI LPDirector, 10% owner10,000,000 shares at $15.27$152.7MMar 6, 2026
SaleWarburg Pincus Partners II, L.P.Director, 10% owner2× since Nov 10, 2025: 33,000,000 shares, avg. $15.48$510.8MMar 6, 2026
SaleWarburg Pincus Partners GP LLCDirector, 10% owner2× since Dec 3, 2025: 24,720,000 shares, avg. $15.69$387.8MMar 6, 2026
SaleGTCR FUND XI/A LPDirector, 10% owner2× since Nov 10, 2025: 18,480,000 shares, avg. $15.89$293.6MDec 3, 2025
SaleWARBURG PINCUS LLCDirector, 10% owner9,720,000 shares at $16.33$158.7MDec 3, 2025
Plus 1 more entries from the last 12 months.
Plus 12 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.84/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+5.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
−12.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−12.2%
Dividend (yield on the price)0.0%
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 27%
2025 sits 61% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+30.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +27.2% a year for the price and +3.0% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: Core sterilization services deliver resilient demand in critical medical and pharma supply chains, yet high leverage with debt exceeding equity and thin evidence remain the key weakness.
Main risk: Integration and pricing risks from tuck-in acquisitions in sterilization could offset expansion gains and pressure margins.
Sotera Health’s core sterilization services support critical medical device and pharma supply chains with resilient demand. Strong cash generation has brought leverage to target levels and opened room for tuck-in M&A in sterilization. Will disciplined acquisitions expand the business enough to close the valuation gap our models see, or will integration and pricing risks offset the gains?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside−67.5% · Bottom 25%
Profitability
Return on equity (12 months)27.0% · Top 25%
Return on assets2.4% · Below median
Net margin (12 months)14.1% · Above median
Operating margin (12 months)35.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)4.4% · Below median
Balance sheet
Debt / equity3.51× · Highest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (12 months)26.7× · Cheaper than median
P/B7.61× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)3.75× · Pricier than median
Price / free cash flow (fiscal year)30.9× · Pricier than median
EV/EBITDA10.9× · Cheaper than median
PEG1.68× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)22· sector 39
PAST (return on equity)100· sector 15
HEALTH (low debt)0· sector 95
DIVIDEND (yield)0· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sotera Health Co Fair Value". https://www.fairvalue-calculator.com/stock/SHC
Frequently asked questions
Is Sotera Health Co (SHC) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $5.20 versus a price of $16.01, about 68% lower (overvalued).
What is the fair value of SHC?
Our model-based fair value for Sotera Health Co is $5.20 (as of Nov 5, 2026), built from audited fundamentals. The current price: $16.01.
What is the quality score of SHC?
Sotera Health Co has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sotera Health Co (SHC)?
Our model-based price target is the fair value of $5.20 (as of Nov 5, 2026) from 22 valuation models. Cautious scenario $2.17, optimistic scenario $8.18. It is a calculation from audited fundamentals, not an analyst target.
What is the Sotera Health Co stock forecast for 2026?
Our models put fair value at $5.20, about 68% lower versus a price of $16.01 (overvalued). Cautious scenario $2.17, optimistic scenario $8.18. The calculation is refreshed regularly with new filings.
What is the revenue of Sotera Health Co (SHC)?
Sotera Health Co reported trailing-twelve-month revenue of about $1.2B (latest available figure, as of Nov 5, 2026).
What growth is priced into Sotera Health Co (SHC)?
For today's price to be fair in a discounted-cash-flow model, Sotera Health Co would have to grow free cash flow by +30.3 % per year for five years (discount rate 12.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.3 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of SHC use?
Our models discount Sotera Health Co at 12.0 %: a base by market capitalisation (mid), damped by beta 1.93, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sotera Health Co that is +30.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.0 %) and the same formula as our fair value.
How much growth has Sotera Health Co (SHC) delivered so far?
Over the past 5 years revenue at Sotera Health Co grew +7.3 % a year. The price currently implies free-cash-flow growth of +30.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sotera Health Co (SHC) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Sotera Health Co (+30.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sotera Health Co (SHC)?
The free-cash-flow yield on the price is 3.23 %: that much free cash flow Sotera Health Co produces per unit of market value. When it exceeds the discount rate of our models (12.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sotera Health Co (SHC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sotera Health Co it is $5.20 per share (as of Nov 5, 2026), against a price of $16.01. It is the blended result of 22 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Sotera Health Co stock overvalued or undervalued in 2026?
As of Nov 5, 2026, SHC trades above its calculated fair value: price $16.01, fair value $5.20, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SHC?
No. The price is what the market pays today ($16.01); the fair value is what the company's own numbers justify ($5.20). For Sotera Health Co the two are $10.81 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sotera Health Co worth?
The market values Sotera Health Co at about $4.6B (market capitalisation, as of Nov 5, 2026). Per share that is $16.01; our models calculate a fair value of $5.20 per share.
What do the bullish and bearish scenarios say about SHC?
Our models span a range for Sotera Health Co: cautious scenario $2.17, base $5.20, optimistic $8.18 per share (as of Nov 5, 2026, price $16.01). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SHC?
Sotera Health Co trades at a price-to-earnings ratio of 26.7 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $5.20 is built from several models across several years. Other multiples: PEG 1.7, P/B 7.6, P/S 3.8, EV/EBITDA 10.9.
What is the PEG ratio of SHC?
The PEG ratio of Sotera Health Co is 1.68 (P/E divided by earnings growth, as of Nov 5, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Sotera Health Co (SHC)?
Balance-sheet figures for Sotera Health Co (as of Nov 5, 2026): return on equity 27.0%, debt of 3.51 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is SHC from its 52-week high?
Sotera Health Co trades at $16.01, about 18% below its 52-week high of $19.57 and 22% above the low of $13.13 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $5.20 is for.
Which stocks are comparable to Sotera Health Co?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sotera Health Co stock attractive at the current price?
The data as of Nov 5, 2026: price $16.01, calculated fair value $5.20 (−68%), Quality Score 50/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SHC calculated?
We run Sotera Health Co through 22 models from 6 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $5.20 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Sotera Health Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sotera Health Co (SHC)?
The closing price on Nov 6, 2026 was $16.01. Our model-based fair value is $5.20, about 68% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sotera Health Co right now?
The price sits above even our optimistic bull case ($8.18). The favourable scenario is already priced in. The model range is unusually wide ($2.17 to $8.18). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Sotera Health Co
How large is the market capitalisation of Sotera Health Co (SHC)?
The market capitalisation of Sotera Health Co is $4.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sotera Health Co (SHC)?
The price-to-sales ratio of Sotera Health Co is 3.75 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sotera Health Co (SHC)?
Earnings per share at Sotera Health Co are $0.6000 (price ÷ EPS = P/E 26.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sotera Health Co (SHC)?
The net margin of Sotera Health Co is 14.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sotera Health Co (SHC)?
The return on equity (ROE) of Sotera Health Co is 27.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sotera Health Co (SHC)?
On an EBIT basis the return on assets of Sotera Health Co is 9.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sotera Health Co (SHC)?
The operating margin of Sotera Health Co is 35.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sotera Health Co (SHC)?
Revenue at Sotera Health Co is growing +4.4% versus a year earlier (3y avg +5.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sotera Health Co (SHC)?
Earnings per share at Sotera Health Co are growing +17.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Sotera Health Co (SHC) carry?
The net debt of Sotera Health Co is $1.9B (fiscal year 2025, ≈ 12.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sotera Health Co in the live analysis
One click puts Sotera Health Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026